• Home
• pregnancy at age 43 symptoms
• Registry Data Show Vedolizumab, Ustekinumab Safe in Pregnancy

Registry Data Show Vedolizumab, Ustekinumab Safe in Pregnancy

4.8 (114) · $ 24.00 · In stock

Full article: Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up

Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease - ScienceDirect

Clearer Perspective on Genetics in IBD; Risankizumab for Treating

Treatment Strategies in Inflammatory Bowel Diseases (10.11.2023)

CSGH

Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn's disease: results from a multicentre cohort study - Péter Bacsur, Mária Matuz

JCM, Free Full-Text

Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study - ScienceDirect

IBD in Pregnancy: Ustekinumab, Vedolizumab Use Appears Safe

Crohn's disease and clinical management today: How it does?